Digital Phenotyping for Retinal Disease - Scorecard - MDSpire

Digital Phenotyping for Retinal Disease

Can your smartphone reveal how you're really coping with vision loss?

  • July 24, 2026

  • 3 min

Share

Clinical Scorecard: Digital Phenotyping for Retinal Disease

At a Glance

CategoryDetail
ConditionInherited Retinal Diseases (IRDs)
Key MechanismsDigital phenotyping using smartphone applications to monitor daily functioning and psychological coping.
Target PopulationPatients with genetically confirmed retinitis pigmentosa (RP) and choroideremia (CHM).
Care SettingClinical research and patient monitoring using digital tools.

Key Highlights

  • Pilot study evaluated feasibility of smartphone-based monitoring in IRD patients.
  • Participants used the OverSight app for passive data collection and patient-reported outcomes.
  • High retention rate of 92% after one year, with over 70% completion of questionnaires.
  • Median of 6,087 steps per day and median walking speed of 1.18 meters per second recorded.
  • Digital phenotyping may complement traditional clinical assessments.

Guideline-Based Recommendations

Diagnosis

    Management

      Monitoring & Follow-up

      • Use of smartphone applications for continuous monitoring of mobility and psychological wellbeing.

      Risks

        Patient & Prescribing Data

        Patients with inherited retinal diseases, specifically RP and CHM.

        Digital phenotyping could provide insights into daily functioning and emotional health.

        Clinical Best Practices

        • Incorporate digital phenotyping as a complementary tool alongside traditional assessments.
        • Utilize validated questionnaires to assess quality of life and psychological factors.

        Related Resources & Content

        Original Source(s)

        Digital Phenotyping for Retinal Disease

        • July 24, 2026

        Related Content

        OLN324: Why Size May Matter

        David A. Eichenbaum, MD, FASRS, and Veeral S. Sheth, MD, MBA, discuss phase 1 JADE findings and how OLN324's small-format design may contribute to improved retinal drying in nAMD and diabetic macular edema.

        OTX-TKI: Inside the SOL-1 Data

        At ASRS 2026, Dilsher S. Dhoot, MD, FASRS, shared additional phase 3 SOL-1 data on vision maintenance, rescue treatment, and safety with investigational OTX-TKI (Axpaxli) in neovascular AMD.

        "Landmark" Dataset Maps Anterior Segment Disease

        Moorfields and UCL launch dataset aiming to accelerate research into anterior segment conditions

        • July 16, 2026

        • 2 min